Tumor response as defined by iRECIST in gastrointestinal malignancies treated with PD-1 and PD-L1 inhibitors and correlation with survival

Código QR

Tumor response as defined by iRECIST in gastrointestinal malignancies treated with PD-1 and PD-L1 inhibitors and correlation with survival

Abstract Background Atypical tumor response patterns during immune checkpoint inhibitor therapy pose a challenge to clinicians and investigators in immuno-oncology practice. This study evaluated tumor burden dynamics to identify imaging biomarkers for treatment response and overall survival (OS) in...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Peiyi Xie, Hong Zheng, Haiyang Chen, Kaikai Wei, Ximin Pan, Qinmei Xu, Yongchen Wang, Changguan Tang, Olivier Gevaert, Xiaochun Meng
Formato:	article
Lenguaje:	EN
Publicado:	BMC 2021
Materias:	PD-1/PD-L1 inhibitor Immunotherapy Advanced gastrointestinal malignancies Tumor response Pseudoprogression Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/d5846f0297f24aa9ad1627f2fb45c329
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Various Uses of PD1/PD-L1 Inhibitor in Oncology: Opportunities and Challenges
por: Zhitao Li, et al.
Publicado: (2021)

The phenomenon of pseudoprogression in cancer immunotherapy: is everything so unambiguous?
por: Vladislav O. Sarzhevskiy, et al.
Publicado: (2021)

Clinical observation of the efficacy of PD‐1/PD‐L1 inhibitors in the treatment of patients with advanced solid tumors
por: Miao Wang, et al.
Publicado: (2021)

Immunotherapy of cancer tumors with inhibition of PD-1 membrane protein and its ligands interaction
por: A. V. Chetveryakov, et al.
Publicado: (2021)

Dl-3-N-Butylphthalide Presents Anti-Cancer Activity in Lung Cancer by Targeting PD-1/PD-L1 Signaling
por: Jiang Q, et al.
Publicado: (2021)

Immunoexpression of PD-L1 and PD-1 and Its Clinicopathological Correlation in Urothelial Carcinomas
por: Utpal Kumar, et al.
Publicado: (2021)

Stomach cancer. Clinical significance of the expression of key components of PD-1/PD-L1 immune checkpoint
por: Olga V. Kovaleva, et al.
Publicado: (2021)

Regulatory Mechanism of PD-L1 Expression in Primary Liver Cancer
por: LI Shenghao, et al.
Publicado: (2021)

The relationship between blood-based tumor mutation burden level and efficacy of PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis
por: He Ba, et al.
Publicado: (2021)

EGCG Inhibits Tumor Growth in Melanoma by Targeting JAK-STAT Signaling and Its Downstream PD-L1/PD-L2-PD1 Axis in Tumors and Enhancing Cytotoxic T-Cell Responses
por: Dinoop Ravindran Menon, et al.
Publicado: (2021)

Synergistic effects of AAGL and anti-PD-1 on hepatocellular carcinoma through lymphocyte recruitment to the liver
por: Xiangdong Ye, et al.
Publicado: (2021)

Treatment-Related Adverse Events with PD-1 or PD-L1 Inhibitors: A Systematic Review and Meta-Analysis
por: Yixi Zhang, et al.
Publicado: (2021)

Anti-PD-1 Therapy—A Potential Treatment for Myocardial Metastasis From Nasopharyngeal Carcinoma: A Case Report
por: Xiaowan Tang, et al.
Publicado: (2021)

Efficacy of PD‐1/PD‐L1 inhibitors in patients with non‐small cell lung cancer and brain metastases: A real‐world retrospective study in China
por: Jiamin Sheng, et al.
Publicado: (2021)

The commensal consortium of the gut microbiome is associated with favorable responses to anti-programmed death protein 1 (PD-1) therapy in thoracic neoplasms
por: Huihui Yin, et al.
Publicado: (2021)

New Insights into the Role of PD-1 and Its Ligands in Allergic Disease
por: Miguel Angel Galván Morales, et al.
Publicado: (2021)

The combination therapy of oncolytic HSV-1 armed with anti-PD-1 antibody and IL-12 enhances anti-tumor efficacy
por: Xin Xie, et al.
Publicado: (2022)

Single-cell RNA sequencing to characterize the response of pancreatic cancer to anti-PD-1 immunotherapy
por: Jing Zhou, et al.
Publicado: (2022)

Relationship between Tumor Mutational Burden, PD-L1, Patient Characteristics, and Response to Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma
por: Kimberly M. Burcher, et al.
Publicado: (2021)

Endocrine Disorders Induced by PD-1/PD-L1 Inhibitor and Related Treatment
por: LAI Yanliang, et al.
Publicado: (2021)

Potential Biomarkers for the Efficacy of PD-1-PD-L Blockade in Cancer
por: Grecea M, et al.
Publicado: (2021)

Anti-PD-1 Immunotherapy Combined With Stereotactic Body Radiation Therapy and GM-CSF as Salvage Therapy in a PD-L1-Positive Patient With Refractory Metastatic Thyroid Hürthle Cell Carcinoma: A Case Report and Literature Review
por: Haihua He, et al.
Publicado: (2021)

The Potential Advantage of Targeting Both PD-L1/PD-L2/PD-1 and IL-10–IL-10R Pathways in Acute Myeloid Leukemia
por: Laura Jimbu, et al.
Publicado: (2021)

Plasmatic Levels of HSP90α at Diagnosis: A Novel Prognostic Indicator of Clinical Outcome in Advanced Lung Cancer Patients Treated With PD-1/PD-L1 Inhibitors Plus Chemotherapy
por: Shubin Chen, et al.
Publicado: (2021)

Application of PD-L1, PD-L2, CD30, CD23 and BCL-6 in Diagnosis and Prognostic Evaluation of Primary Mediastinal Large B-cell Lymphoma
por: YUAN Ting, et al.
Publicado: (2021)

Different Induction of PD-L1 (CD274) and PD-1 (CD279) Expression in THP-1-Differentiated Types 1 and 2 Macrophages
por: Lai CY, et al.
Publicado: (2021)

Immune-Related Adverse Events in PD-1 Treated Melanoma and Impact Upon Anti-Tumor Efficacy: A Real World Analysis
por: Melissa L. Bastacky, et al.
Publicado: (2021)

Activity of PD-1 Inhibitor Combined With Anti-Angiogenic Therapy in Advanced Sarcoma: A Single-Center Retrospective Analysis
por: Yang You, et al.
Publicado: (2021)

Clinicoprognostic and Histopathological Features of Guttate and Plaque Psoriasis Based on PD-1 Expression
por: Chang-Jin Jung, et al.
Publicado: (2021)

Differential Role of PD-1 Expressed by Various Immune and Tumor Cells in the Tumor Immune Microenvironment: Expression, Function, Therapeutic Efficacy, and Resistance to Cancer Immunotherapy
por: Myeong Joon Kim, et al.
Publicado: (2021)

Conditional Deletion of Pdcd1 Identifies the Cell-Intrinsic Action of PD-1 on Functional CD8 T Cell Subsets for Antitumor Efficacy
por: Sukanya Raghavan, et al.
Publicado: (2021)

Endoglin-Aptamer-Functionalized Liposome-Equipped PD-1-Silenced T Cells Enhance Antitumoral Immunotherapeutic Effects
por: Xie S, et al.
Publicado: (2021)

PD-L1 Inhibitors: Different Classes, Activities, and Mechanisms of Action
por: Ewa Surmiak, et al.
Publicado: (2021)

Safety of thoracic radiotherapy after PD‐(L)1 inhibitor treatment in patients with lung cancer
por: Yu Chen, et al.
Publicado: (2021)

The effect of hypoxia on PD-L1 expression in bladder cancer
por: Vicky Smith, et al.
Publicado: (2021)

The Importance of Exosomal PD-L1 in Cancer Progression and Its Potential as a Therapeutic Target
por: Lingxiao Ye, et al.
Publicado: (2021)

Large cell morphology, CMYC+ tumour cells, and PD-1+ tumour cell/intense PD-L1+ cell reactions are important prognostic factors in nodal peripheral T-cell lymphomas with T follicular helper markers
por: Yasuhito Mihashi, et al.
Publicado: (2021)

Reconstitution of Monocyte Subsets and PD-L1 Expression but Not T Cell PD-1 Expression in Obstructive Sleep Apnea Patients upon PAP Therapy
por: Christina Polasky, et al.
Publicado: (2021)

Efficacy and Safety of PD-1 Inhibitor Combined with Anlotinib on Advanced Neuroendocrine Carcinoma
por: YU Xuxu, et al.
Publicado: (2021)

Improved resection and prolonged overall survival with PD-1-IRDye800CW fluorescence probe-guided surgery and PD-1 adjuvant immunotherapy in 4T1 mouse model
por: Du Y, et al.
Publicado: (2017)